N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH

[1]  H. Rickli,et al.  N‐terminal pro‐brain natriuretic peptide used for the prediction of coronary artery stenosis , 2007, European journal of clinical investigation.

[2]  G. Lip,et al.  N‐terminal pro‐brain natriuretic peptide and coronary artery disease , 2007, European journal of clinical investigation.

[3]  O. Distler,et al.  Pulmonary arterial hypertension and rheumatic diseases--from diagnosis to treatment. , 2006, Rheumatology.

[4]  S. Iliceto,et al.  Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases , 2006, European journal of clinical investigation.

[5]  C. Denton,et al.  Systemic sclerosis associated pulmonary hypertension: improved survival in the current era , 2005, Heart.

[6]  C. Denton,et al.  Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. , 2006, European heart journal.

[7]  Sandra Braun,et al.  Niveles de péptido natriurético cerebral y su relación con capacidad funcional y hemodinamia pulmonar en pacientes con hipertensión pulmonar primaria: Correlation with functional capacity and hemodynamic parameters , 2006 .

[8]  P. Castro,et al.  [Brain natriuretic peptide in primary pulmonary hypertension]. , 2006, Revista medica de Chile.

[9]  J. Seibold,et al.  Bosentan in pulmonary arterial hypertension secondary to scleroderma. , 2006, The Journal of rheumatology.

[10]  R. Souza,et al.  Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension , 2005, Current medical research and opinion.

[11]  S Gary Firestein,et al.  Kelley's Textbook of Rheumatology , 2004 .

[12]  D. Borderie,et al.  N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. , 2003, Arthritis and rheumatism.

[13]  A. Holmes,et al.  Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. , 2003, Respiratory medicine.

[14]  M. Davies,et al.  Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations , 2002, BMJ : British Medical Journal.

[15]  Avid,et al.  BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .

[16]  D. Badesch,et al.  Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.